BioWorld

May 15, 2007

Targanta Seeks $86M In IPO For Antibiotic Development

As it prepares to file a new drug application for the antibiotic oritavancin in the first quarter of 2008, Targanta Therapeutics Corp. filed to raise $86.25 million in an initial public offering. (BioWorld Today) Read More

Critical Therapeutics' Shares Rise On Perforomist Approval

Complementary Approaches Snare New Huntington's Targets

Neurotech-Focused Parties Come Together Under NIO

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...